John H Newman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8075514/publications.pdf

Version: 2024-02-01

279487 214527 4,150 48 23 47 citations h-index g-index papers 48 48 48 4766 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Right Heart Adaptation to Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2013, 62, D22-D33.	1.2	770
2	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	1.2	605
3	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S32-S42.	1.2	342
4	Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nature Genetics, 1997, 15, 277-280.	9.4	260
5	Genetic basis of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S33-S39.	1.2	227
6	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	1.1	185
7	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183
8	Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1936-1944.	1.6	169
9	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2525-2536.	1.2	160
10	Association of the Metabolic Syndrome With Pulmonary Venous Hypertension. Chest, 2009, 136, 31-36.	0.4	157
11	High Prevalence of Occult Pulmonary Venous Hypertension Revealed by Fluid Challenge in Pulmonary Hypertension. Circulation: Heart Failure, 2014, 7, 116-122.	1.6	151
12	Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies. Annals of Internal Medicine, 2008, 148, 278.	2.0	83
13	Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 719-728.	2.5	7 5
14	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. Circulation, 2015, 131, 401-409.	1.6	72
15	Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension. Nature Communications, 2015, 6, 6863.	5.8	69
16	Physical Activity Limitation as Measured by Accelerometry in Pulmonary Arterial Hypertension. Chest, 2012, 142, 1391-1398.	0.4	66
17	Causes of Pulmonary Hypertension in the Elderly. Chest, 2014, 146, 159-166.	0.4	54
18	Limitations of exome sequencing in detecting rare and undiagnosed diseases. American Journal of Medical Genetics, Part A, 2020, 182, 1400-1406.	0.7	51

#	Article	IF	Citations
19	High-Altitude Pulmonary Hypertension in Cattle (Brisket Disease): Candidate Genes and Gene Expression Profiling of Peripheral Blood Mononuclear Cells. Pulmonary Circulation, 2011, 1, 462-469.	0.8	46
20	Six-minute walk distance in healthy young adults. Respiratory Medicine, 2020, 165, 105933.	1.3	43
21	Use of Pulmonary Arterial Hypertension–Approved Therapy in the Treatment of Non–Group 1ÂPulmonary Hypertension at US Referral Centers. Pulmonary Circulation, 2015, 5, 356-363.	0.8	39
22	Hemodynamic Evidence of Vascular Remodeling in Combined Post―and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	0.8	38
23	Prostanoids But Not Oral Therapies ImproveÂRight Ventricular Function in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2013, 1, 300-307.	1.9	31
24	Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. American Journal of Human Genetics, 2021, 108, 1946-1963.	2.6	25
25	Lungs at high-altitude: genomic insights into hypoxic responses. Journal of Applied Physiology, 2015, 119, 1-15.	1.2	24
26	Effect of Acute Arteriolar Vasodilation on Capacitance and Resistance in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1080-1085.	0.4	20
27	Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 624-634.	0.8	20
28	End Tidal CO 2 Tension. Chest, 2011, 140, 1267-1273.	0.4	19
29	Whole genome sequencing reveals novel <i>IGHMBP2</i> variant leading to unique cryptic spliceâ€site and Charcotâ€Marieâ€Tooth phenotype with early onset symptoms. Molecular Genetics & Denomic Medicine, 2019, 7, e00676.	0.6	18
30	Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. Genetics in Medicine, 2021, 23, 259-271.	1.1	18
31	<i>BMPR2</i> dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L429-L441.	1.3	17
32	Familial Autonomic Ganglionopathy Caused by Rare <i>CHRNA3</i> Genetic Variants. Neurology, 2021, 97, e145-e155.	1.5	12
33	Phenotypic heterogeneity of ZMPSTE24 deficiency. American Journal of Medical Genetics, Part A, 2018, 176, 1175-1179.	0.7	11
34	Pulmonary Hypertension by the Method of Paul Wood. Chest, 2020, 158, 1164-1171.	0.4	11
35	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
36	Characterization of Immunopathology and Small Airway Remodeling in Constrictive Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	11

#	Article	IF	CITATIONS
37	lgG4â€related disease: Association with a rare gene variant expressed in cytotoxic T cells. Molecular Genetics & Genomic Medicine, 2019, 7, e686.	0.6	8
38	Rare Variants in the Gene ALPL That Cause Hypophosphatasia Are Strongly Associated With Ovarian and Uterine Disorders. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2234-2243.	1.8	7
39	Variability in Hemodynamic Evaluation of Pulmonary Hypertension at Large Referral Centers. Pulmonary Circulation, 2014, 4, 679-684.	0.8	6
40	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 896-902.	1.5	6
41	Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy. Clinical Imaging, 2019, 58, 108-113.	0.8	6
42	Phenotypic Profiling in Subjects Heterozygous for 1 of 2 Rare Variants in the Hypophosphatasia Gene (ALPL). Journal of the Endocrine Society, 2020, 4, bvaa084.	0.1	6
43	Vascular homeostasis at highâ€altitude: role of genetic variants and transcription factors. Pulmonary Circulation, 2020, 10, 1-11.	0.8	6
44	One is the loneliest number: genotypic matchmaking using the electronic health record. Genetics in Medicine, 2021, 23, 1830-1832.	1.1	6
45	Clinical Trials in Pulmonary Hypertension: Time for a Consortium. Pulmonary Circulation, 2013, 3, 245-251.	0.8	4
46	The First Annual Drug Discovery and Development Symposium for Pulmonary Hypertension. Pulmonary Circulation, 2014, 4, 533-534.	0.8	1
47	Design and Effectiveness of an Animated Module that Integrates Basic and Clinical Pulmonary Mechanics for Medical Students. Medical Science Educator, 2015, 25, 13-18.	0.7	1
48	Chasing Pulmonary Hypertension: 1980–2012. Advances in Pulmonary Hypertension, 2012, 11, 121-123.	0.1	0